Regulatory approval

Published by the Health Service Executive. Approved

Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations

This is written in the approval document.

Reimbursement

CDS

Citation

Dacomitinib Monotherapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6894/565_V3_Dacomitinib.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	EGFR activating variants	Non-Small Cell Lung Cancer	Dacomitinib

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2019-11-01	Health Service Executive	Indication approved for reimbursement.